Holen Sie sich die Stockscreener-App
0.4612
3.92%
-0.0188
Handel nachbörslich:
.46
-0.0012
-0.26%
Schlusskurs vom Vortag:
$0.48
Offen:
$0.46
24-Stunden-Volumen:
335.73K
Relative Volume:
2.18
Marktkapitalisierung:
$64.69M
Einnahmen:
$121.91M
Nettoeinkommen (Verlust:
$1.83M
KGV:
42.31
EPS:
0.0109
Netto-Cashflow:
$7.75M
1W Leistung:
+0.48%
1M Leistung:
-12.00%
6M Leistung:
-26.17%
1J Leistung:
-37.40%
1-Tages-Spanne:
$0.46
$0.4799
1-Wochen-Bereich:
$0.45
$0.4946
52-Wochen-Spanne:
$0.438
$0.95
Xtant Medical Holdings Inc Stock (XTNT) Company Profile
Firmenname
Xtant Medical Holdings Inc
Sektor
Branche
Telefon
406-388-0480
Adresse
664 Cruiser Lane, Belgrade, MT
Compare XTNT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XTNT
Xtant Medical Holdings Inc
|
0.4612 | 67.33M | 121.91M | 1.83M | 7.75M | 0.0109 |
ABT
Abbott Laboratories
|
86.66 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.95 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.59 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.66 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.56 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Xtant Medical Holdings Inc Stock (XTNT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-05 | Eingeleitet | BTIG Research | Buy |
| 2018-11-15 | Bestätigt | Maxim Group | Buy |
| 2018-02-14 | Bestätigt | Maxim Group | Buy |
Xtant Medical Holdings Inc Aktie (XTNT) Neueste Nachrichten
Xtant outlines $95M-$99M 2026 revenue outlook as Companion Spine divestiture and Q-code license revenue roll off - MSN
XTNT Q1 2026 Earnings: EPS Misses Estimates Despite Stock GainCommunity Hot Stocks - Newser
Xtant Medical Holdings Inc. (XTNT) Q1 2026 Earnings: EPS Misses Estimates Amidst Narrow LossSenior Analyst Forecasts - Newser
Xtant Medical Holdings (XTNT) Edges Higher: Testing Key Resistance at $0.50Shared Buy Zones - Newser
Xtant Medical Holdings Holds Near Key Resistance Level After Modest GainCommunity Chart Signals - Newser
Xtant Medical Holdings (XTNT) Gains 2.08% as Stock Approaches Key Resistance at $0.50Profitability Factor - Newser
Xtant Medical Balances New Growth Bets With Near-Term Pain - TipRanks
Xtant Medical launches pre-shaped bone graft product line By Investing.com - Investing.com Nigeria
XTNT SEC FilingsXtant Medical 10-K, 10-Q, 8-K Forms - Stock Titan
Xtant Medical raises FY 2026 revenue guidance to $101M-$105M as it adds HEMOBLAST distribution rights - MSN
Xtant Medical Q1 Earnings Call Highlights - Yahoo Finance
B. Riley Financial | Diversified Financial Services Platform - FinancialContent
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Xtant Medical Holdings’ revenue drops to USD 20.9M in Q1 2026 - Medical Buyer
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2026 Earnings Call Transcript - Insider Monkey
Xtant Medical Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Xtant Medical Boosts 2026 Outlook Amid Tough Quarter - TipRanks
Xtant Medical Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Xtant Medical Holdings Inc Q1 2026 Earnings: Revenue Misses $20.9 million - technotrenz.com
Xtant Medical Holdings, Inc. 2026 Q1 10-Q Report: Financial Results, Strategic Initiatives, and Key Risk Factors - Minichart
Xtant Medical Q1 2026 Results: Revenue Guidance Raised, Balance Sheet Strengthened, Exclusive HEMOBLAST® Bellows Distribution Secured 12 - Minichart
Xtant Medical Q1 2026 Earnings Call Transcript - MarketBeat
XTNT: Raised 2026 revenue guidance to $101M–$105M amid new product launches and reduced debt - TradingView
Xtant Medical Reports First Quarter 2026 Results and Raises Guidance - HarianBasis.co
Xtant Medical Hldgs Q1 2026 Earnings Call Transcript - Yahoo Finance
Xtant Medical launches Trivium Shaped allograft for surgeries - MSN
Xtant Medical Updates Q1 Results and Raises 2026 Guidance - TipRanks
XTNT: Q1 2026 revenue dropped 37% and net loss reached $3.1M amid asset sales and reimbursement shifts - TradingView
Xtant Medical (XTNT) Q1 2026 revenue drops 37% as divestitures hit sales - Stock Titan
XTNT: Raised 2026 revenue guidance to $101–$105M amid asset sales, new product launches, and debt reduction - TradingView
Xtant Medical (NYSE: XTNT) cuts debt, raises 2026 revenue guidance after Q1 - Stock Titan
Press Release: Xtant Medical Reports First Quarter 2026 Financial Results - Moomoo
MSN Money - MSN
TradingKey - TradingKey
Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped - Orthopedics This Week
May 13 before trading: Xtant Medical posts Q1 results, 8:30 ET call - Stock Titan
Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026 - Morningstar
Xtant Medical launches pre-shaped bone graft product line - Investing.com UK
Xtant rolls out ready-to-use bone graft forms for spine surgery - Stock Titan
Finanzdaten der Xtant Medical Holdings Inc-Aktie (XTNT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
2.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):